Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using non-invasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. In addition, functional imaging technologies, such as PET, can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Regardless, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.

Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using noninvasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. Moreover, functional imaging technologies such as PET can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Anyway, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.

The success of boron neutron capture therapy (BNCT) depends mainly on sufficient spatial biodistribution of boron (B-10) localized around or within neoplastic cells to produce a high dose gradient between the tumor and healthy tissue. Contrary to what is usual in radiotherapy, BNCT proposes treatment planning directed at the cell rather than the tumor mass. However, it is not yet possible to precisely determine the concentration of B-10 in a specific tissue in real-time using non-invasive methods. Some critical issues still need to be resolved if BNCT is to become a valuable, minimally invasive, and efficient cancer treatment. This review article provides an overview of the funda-mental principles, recent advances, and future directions of BNCT as a cell-targeted cancer therapy. The main emphasis is on topics related to biological dosimetry, methods for assessing boron concentration, mechanisms of action of BNCT, and its physical bases for clinical implementation.

The success of boron neutron capture therapy(BNCT) mainly depends on sufficient spatial bio-distribution of boron(10B) localized around or within the neoplastic cells to produce a high dose gradient between the tumor and healthy tissue. Contrary to what is usual in radiotherapy, BNCT proposes treatment planning directed at the cell instead of the tumor mass. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using non-invasive methods. Some critical issues still need to be resolved if BNCT is to become valuable, minimally invasive, and efficient cancer treatment. This review article provides an overview of fundamental principles, the recent advances, and future directions of BNCT as cellular targeted cancer therapy. The main emphasis is on topics related to biological dosimetry, methods for as-sessment of boron concentration, mechanisms of action of BNCT, and its physical bases for clinical implementation.